A dose of gamma rays from Elekta won't turn you into the Incredible Hulk, but it could make you feel like him. The company manufactures the Gamma Knife -- which isn't a knife at all but a chamber that delivers radiation therapy to treat tumors and cancer in the brain. The Gamma Knife was invented in 1968 by Elekta's founder, Dr. Lars Leksell, the father of radiosurgery. Elekta manufactures other non-invasive treatment systems, such as image-guided radiation therapy (IRGT) and particle therapy, used to treat cancer elsewhere in the body. Elekta was founded in 1972. Its products are used in more than 5,000 hospitals around the world.

Elekta maintains its presence in the radiology and oncology fields by introducing its established treatment systems to new geographical segments, such as Asia and Eastern Europe. Its three primary geographical areas of focus are: North and South America; Europe, Middle East, Africa; and Asia/Pacific. In 2012, for example, the company strengthened its position in Brazil by acquiring Radon Ltda. group, Brazil's leading linear accelerator (linac) service company.

The company's four divisions are Oncology, Neuroscience, Software, and Services. Elekta's software division includes electronic medical records (EMR), archiving, retrieval, and management of data, tools to streamline clinical and business operations, and treatment planning covering the spectrum of radiation therapy, radiosurgery, and particle therapy techniques. Elekta provides services such as remote clinical optimization, education and training, and consulting, among others.

Elekta's software division intends to seek US customers who are eligible for funding from President Obama's Health Information Technology for Economic and Clinical Health (HITECH) Act. The $19 billion plan allows the US health care industry to upgrade to EMRs, which Elekta can administer.

The company grows its product offerings through new development and selective acquisitions. In 2010 Elekta acquired Resonant Medical, a Montreal-based company that added additional non-invasive image guidance technology to Elekta's portfolio. The new line of products allows oncologists to view soft tissue such as breast tissue and the prostate.

Moving into a new therapeutic area after years of IT growth, Elekta acquired Dutch radiotherapy firm Nucletron for some €365 million ($500 million) in 2011. The purchase added brachytherapy devices for treating cancer by implanting radioactive seeds in tumor areas; it also expanded the company's presence in the radiotherapy market as brachytherapy and external beam radiation therapies are increasingly being used in tandem to treat certain cancers. Nucletron's systems are used in about 1,000 medical facilities worldwide.

Elekta also collaborates with medical centers to educate providers and patients about new cancer care delivery options. The partnerships cover the spectrum of cancer treatment from planning and delivery to workflow and connectivity to increase the centers' access to new technology.

Some of Elekta's newly-launched technologies include its image-guidance solutions, Intuity and Symmetry, that provide higher clinical precision. The company also launched a new platform for Elekta Neuromag that allows researchers and clinicians to map brain activity.

The company is counting on sales of its new products as well as its roster of oldies but goodies to keep its sales figures up. Net sales grew by 11% in 2010 and operating results increased by 48%, thanks to higher volumes, efficiency improvements, and a little help from positive currency exchanges in some places. In order to keep those figures up, Elekta will have to keep an eye on political decisions that could impact reimbursement levels, in the US and elsewhere. Negative reimbursement levels generally lead to reduced health care spending, in both the private and public sectors.

Dr. Leksell's son, Dr. Laurent Leksell, is the company's single-largest individual shareholder. Laurent Leksell headed Elekta as CEO from its start in 1972 (when he was 20) until 2005. He now sits on the board of directors and on the executive committee. Dr. Lars Leksell died in 1986.

- Show Less + Show Full Description


13723 Riverport Dr Ste 100
Maryland Heights, MO 63043
Phone: 1 (314) 993-0003
Fax: 1 (314) 919-0274


  • Employer Type: Public
  • Partner, Strategic Business Solutions: Adam Akbany
  • Chairman: Yasuo Ashino
  • Ceo: Tim Mortenson

Major Office Locations

  • Maryland Heights, MO